AbbVie Inc vs Energy Select Sector SPDR Fund — how do they compare? AbbVie Inc trades at $249.5 (market cap $438.19B), while Energy Select Sector SPDR Fund trades at $60.78. The key difference: AbbVie Inc pays a 2.79% dividend while Energy Select Sector SPDR Fund pays none, and Energy Select Sector SPDR Fund is trading nearer its 52-week high, AbbVie Inc nearer its low. Which is the better fit depends on your goals.
| ABBV | XLE | |
|---|---|---|
Market Cap | $438.19B | — |
Sector | Health | — |
52-Week High | $263.58 | $62.57 |
52-Week Low | $197.38 | $42.33 |
Enterprise Value | $502.45B | — |
Dividend Yield | 2.79% | — |
Signals from Pluang's Aura AI — not financial advice
ABBV trades at $247.91, up 0.76% today, with a bullish technical signal supported by moving averages and oversold RSI levels. The company reported Q2 2026 EPS of $3.65, beating expectations, and maintains strong profitability with a 71.48% gross margin. Recent news highlights positive Phase 2 data for ELAHERE in ovarian cancer, reinforcing growth prospects beyond Humira's patent expiry.
Outlook is positive with analyst consensus target of $278.69, though high P/E of 70.05 and debt levels pose valuation and financial risks. Revenue growth driven by Skyrizi and Rinvoq offsets competitive pressures, but patent cliffs in the 2030s require monitoring. The stock offers dividend appeal with a $1.73 payout scheduled for August 2026.
XLE (Energy Select Sector SPDR ETF) trades at $57.48, down 1.17% amid bearish technical signals. The ETF faces headwinds despite strong energy sector performance driven by geopolitical tensions and elevated oil prices. Recent earnings from major holdings like ExxonMobil and Chevron showed profit surges, but technical indicators suggest near-term weakness with resistance at $58 and support at $57.
Outlook remains mixed with geopolitical risks supporting oil prices but technical weakness suggesting caution. The concentrated exposure to major energy companies provides stability but limits diversification. Key risks include oil price volatility and Middle East tensions, while the low expense ratio of 0.08% maintains cost efficiency for long-term energy exposure.
Trailing returns across standard periods
Latest headlines on both assets
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as energy companies by the GICS®, including securities of companies from the following industries: oil, gas and consumable fuels; and energy equipment and services. It is non-diversified.
Read more on XLE →